688136 Stock Overview
Engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Kexing Biopharm Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.93 |
| 52 Week High | CN¥22.82 |
| 52 Week Low | CN¥10.61 |
| Beta | 0.85 |
| 11 Month Change | -8.73% |
| 3 Month Change | 14.16% |
| 1 Year Change | -15.43% |
| 33 Year Change | -43.64% |
| 5 Year Change | n/a |
| Change since IPO | -58.72% |
Recent News & Updates
Recent updates
There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise
Oct 08
Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too
May 21Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%
Mar 08Shareholder Returns
| 688136 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -2.8% | -1.9% | -2.8% |
| 1Y | -15.4% | -21.0% | 2.0% |
Return vs Industry: 688136 exceeded the CN Biotechs industry which returned -21% over the past year.
Return vs Market: 688136 underperformed the CN Market which returned 2% over the past year.
Price Volatility
| 688136 volatility | |
|---|---|
| 688136 Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688136 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688136's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,014 | Yanqing Zhao | www.kexing.com |
Kexing Biopharm Co., Ltd. engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally. The company focuses on pharmaceutical research in the therapeutic fields of antiviral, tumor and immunity, blood, digestion, and degenerative diseases. Its products include recombinant human interferon a1b, human erythropoietin, and human granulocyte stimulating factor; Clostridium butyricum combined live bacteria powder; Kehuang Capsule, a Chinese patent medicine; Entecavir, a chemical drug; and liraglutide, a human glucagon-like peptide-1, as well as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules.
Kexing Biopharm Co., Ltd. Fundamentals Summary
| 688136 fundamental statistics | |
|---|---|
| Market cap | CN¥3.34b |
| Earnings (TTM) | -CN¥118.80m |
| Revenue (TTM) | CN¥1.33b |
2.5x
P/S Ratio-28.1x
P/E RatioIs 688136 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688136 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.33b |
| Cost of Revenue | CN¥407.21m |
| Gross Profit | CN¥921.08m |
| Other Expenses | CN¥1.04b |
| Earnings | -CN¥118.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 69.34% |
| Net Profit Margin | -8.94% |
| Debt/Equity Ratio | 69.9% |
How did 688136 perform over the long term?
See historical performance and comparison